Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

Rhea-AI Summary

Zimmer Biomet (NYSE: ZBH) appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. He will report to Ivan Tornos and oversee the company's global technology portfolio, including AI, robotics, smart implants and data, plus Medical Education and the Global Advisory Board.

Dr. Vigdorchik joins from Hospital for Special Surgery, previously served as Zimmer Biomet Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, and holds academic roles including Associate Professor at Weill Cornell.

Positive

• Appointment effective April 14, 2026
• Will oversee AI, robotics, smart implants and data portfolio
• Reports directly to CEO Ivan Tornos
• Brings clinical leadership from Hospital for Special Surgery and academic roles

Negative

• None.

News Market Reaction – ZBH

+0.44%

+0.44% News Effect

On the day this news was published, ZBH gained 0.44%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Zimmer Biomet’s focus on AI, robotics, smart implants and data by appoi...

Analysis

This announcement highlights Zimmer Biomet’s focus on AI, robotics, smart implants and data by appointing a senior leader to oversee its global technology and medical affairs strategy. In recent months, the company has paired innovation messaging with solid financial results and shareholder returns, including dividends and buybacks. Investors may watch how this role influences the execution of its robotics and digital roadmap alongside previously communicated revenue and EPS guidance for 2026.

Key Figures

Q4 2025 net sales: $2.244B FY 2025 net sales: $8.232B Q4 2025 adj. EPS: $2.42 +5 more

8 metrics

Q4 2025 net sales $2.244B Fourth quarter 2025 results

FY 2025 net sales $8.232B Full-year 2025 results

Q4 2025 adj. EPS $2.42 Fourth quarter 2025 adjusted EPS

FY 2025 adj. EPS $8.20 Full-year 2025 adjusted EPS

Operating cash flow $1.697B Full-year 2025 operating cash flow

Free cash flow $1.172B Full-year 2025 free cash flow

Share repurchase auth. $1.5B New authorization commencing Feb 9, 2026

2026 EPS guidance $8.30–$8.45 Full-year 2026 adjusted EPS target range

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Conference innovations	Positive	-0.0%	Planned data releases and technology showcases at AAOS 2026 meeting.
Feb 23	Dividend declaration	Positive	+0.7%	Announcement of Q1 2026 quarterly cash dividend of $0.24 per share.
Feb 10	Earnings results	Positive	+1.9%	Q4 and full-year 2025 results with growth, cash generation and guidance.
Jan 15	Earnings call setup	Neutral	-0.6%	Scheduling and access details for Q4 2025 earnings webcast and call.
Dec 22	Conference presentation	Positive	+0.8%	Planned management presentation at J.P. Morgan Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including earnings and dividend announcements, generally saw modest positive price alignment, with one small divergence on an innovation-focused conference update.

Recent Company History

Over the last several months, Zimmer Biomet has emphasized innovation and shareholder returns. Earnings on Feb 10, 2026 highlighted higher sales, strong cash generation, and new share repurchase capacity. A quarterly dividend was announced on Feb 23, 2026, while conference and meeting participation underscored its robotic and digital portfolio. Against this backdrop, today’s leadership appointment in science, technology, and medical affairs fits the ongoing focus on advancing robotics, AI, and implant innovation.

Key Terms

ai, robotics, smart implants, medical education, +1 more

5 terms

ai technical

"technology portfolio, including AI, robotics, smart implants and data."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

robotics technical

"technology portfolio, including AI, robotics, smart implants and data."

Robotics is the design, building and programming of machines that can perform physical tasks autonomously or with minimal human control, ranging from simple mechanical helpers to complex intelligent systems. For investors, robotics matters because these machines can boost productivity, cut operating costs, and create new markets much like adding a team of tireless, precise workers; companies that develop or adopt robotics can gain competitive advantages and shift future revenue and expenses.

smart implants technical

"technology portfolio, including AI, robotics, smart implants and data."

Small medical devices placed inside the body that combine sensors, electronics, and sometimes drug delivery or wireless communication to monitor, support, or adjust biological functions—think of them as tiny computers or thermostats implanted to track or influence health. Investors care because they sit at the intersection of healthcare and technology, offering recurring revenue from device sales, software upgrades, and data services, while regulatory approval, safety, and adoption determine commercial success and risk.

medical education medical

"He will also oversee Zimmer Biomet's Medical Education strategy and Global Advisory Board,"

The organized teaching and training of doctors, nurses and other health professionals across initial degrees, hands‑on clinical training and ongoing refresher courses that keep skills and knowledge current. For investors it matters because it creates steady demand for education services, training technologies, certification programs and related products; strong medical education pipelines influence workforce quality, product adoption and regulatory readiness, much like continuing certification keeps other professions competent and marketable.

orthopaedic surgery medical

"He is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College."

Orthopaedic surgery is the medical specialty that diagnoses and treats problems with bones, joints, ligaments, tendons and muscles, often through operations like joint replacements, fracture repairs and spinal procedures. Investors care because these surgeries drive demand for implants, surgical devices, hospital services and follow-up care—similar to how a car-repair shop creates steady business for parts makers and tools—so changes in procedure volumes, technology approvals or reimbursement can materially affect company revenues.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity

WARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14.

In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet's Medical Education strategy and Global Advisory Board, helping further strengthen Zimmer Biomet's clinical engagement, innovation roadmap and external scientific leadership. Dr. Vigdorchik will report to Ivan Tornos, Chairman, President and Chief Executive Officer.

"Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care," said Tornos. "He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger and continue advancing our broad suite of robotic and enabling technologies. I'm confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market."

Dr. Vigdorchik previously served as Zimmer Biomet's Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik held several prominent academic and clinical leadership positions, including serving as Division Chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and Director of Bone Implant Longevity Research at HSS's Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting.

"As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics," said Dr. Vigdorchik. "I've dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I'm excited to join the talented team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world."

Dr. Vigdorchik earned his medical degree from the University of Missouri – Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children's Hospital, and Washington University in St. Louis.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

Contacts:   Media Troy Kirkpatrick 614-284-1926 troy.kirkpatrick@zimmerbiomet.com   Kirsten Fallon 781-779-5561 kirsten.fallon@zimmerbiomet.com

Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com   Zach Weiner 908-591-6955 zach.weiner@zimmerbiomet.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-appoints-dr-jonathan-m-vigdorchik-as-chief-science-technology-and-medical-affairs-officer-302735027.html

SOURCE Zimmer Biomet Holdings, Inc.

FAQ

When does Jonathan Vigdorchik start as Chief Science, Technology and Medical Affairs Officer at ZBH?

He begins the role on April 14, 2026. According to Zimmer Biomet, he will immediately assume oversight of the company’s global technology portfolio and related medical affairs functions.

What responsibilities will Dr. Jonathan Vigdorchik have at ZBH?

He will oversee strategy and delivery for AI, robotics, smart implants and data. According to Zimmer Biomet, he will also manage Medical Education and the Global Advisory Board to strengthen clinical engagement.

Who does Dr. Vigdorchik report to at Zimmer Biomet (ZBH)?

Dr. Vigdorchik reports to Ivan Tornos, Chairman, President and CEO. According to Zimmer Biomet, this places him within the senior leadership team driving technology and medical strategy.

What is Dr. Vigdorchik’s clinical and academic background relevant to ZBH (ZBH)?

He is a board-certified orthopedic surgeon at Hospital for Special Surgery and Associate Professor at Weill Cornell. According to Zimmer Biomet, he previously served as the company’s Chief Medical Technology Advisor for adult reconstruction.

How might Dr. Vigdorchik’s appointment affect Zimmer Biomet’s robotics and AI roadmap?

The appointment signals elevated focus on robotics and AI integration across products. According to Zimmer Biomet, he will help accelerate the portfolio strategy and advance the company’s robotic and enabling technologies.